Trial Spotlight

FORAGER-1; NCT05614739

A Phase 1, Open-label, Multicenter Study of LY3866288 (LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer with FGFR3 Alterationsa

Filter our pipeline to find information relevant to you. Search results will appear below.
Recruiting

Breast

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
CDK4/6 Inhibitor
3
Active, not recruiting
CDK4/6 Inhibitor
3
Active, not recruiting
CDK4/6 Inhibitor
3
Active, not recruiting
CDK4/6 Inhibitor
3
Active, not recruiting
FRα Antibody-Drug Conjugate
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 1
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 2
1
Active, not recruiting
Selective Estrogen Receptor Degrader
1
Active, not recruiting
Selective Estrogen Receptor Degrader
3
Active, not recruiting
Selective Estrogen Receptor Degrader
3
Recruiting

Gastrointestinal

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
FRα Antibody-Drug Conjugate
1
Recruiting
KRAS G12C Inhibitor
2
Recruiting
KRAS G12D Inhibitor
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 1
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 2
1
Active, not recruiting
Pan-KRAS Inhibitor
1
Recruiting

Genitourinary

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
FGFR3 Inhibitor
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 1
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 2
1
Active, not recruiting
Prostate-Specific Membrane Antigen (PSMA) Radioligand
1
Recruiting

Gynecologic

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
FRα Antibody-Drug Conjugate
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 1
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 2
1
Active, not recruiting
Selective Estrogen Receptor Degrader
1
Active, not recruiting

Hematologic

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
BAFF-R T-Cell Engager
PRECLINICAL
BTK Inhibitor
2
Active, not recruiting
BTK Inhibitor
3
Active, not recruiting
BTK Inhibitor
3
Active, not recruiting
BTK Inhibitor
3
Active, not recruiting
BTK Inhibitor
3
Active, not recruiting
BTK Inhibitor
3
Active, not recruiting

Lung

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
FRα Antibody-Drug Conjugate
1
Recruiting
KRAS G12C Inhibitor
2
Recruiting
KRAS G12C Inhibitor
3
Recruiting
KRAS G12C Inhibitor
3
Recruiting
KRAS G12D Inhibitor
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 1
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 2
1
Active, not recruiting
Pan-KRAS Inhibitor
1
Recruiting
PTK7 Antibody-Drug Conjugate
PRECLINICAL
RET Inhibitor
3
Active, not recruiting
RET Inhibitor
3
Active, not recruiting
SMARCA2 (BRM) Inhibitor
1
Recruiting
VEGF Receptor-2 Antagonist
3
Active, not recruiting

Other Solid Tumors

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
CDK4/6 Inhibitor
2
Active, not recruiting
CDK4/6 Inhibitor
2
Recruiting
FGFR3 Inhibitor
1
Recruiting
KRAS G12C Inhibitor
2
Recruiting
KRAS G12D Inhibitor
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 1
1
Recruiting
Nectin-4 Antibody-Drug Conjugate 2
1
Active, not recruiting
Pan-KRAS Inhibitor
1
Recruiting
PTK7 Antibody-Drug Conjugate
PRECLINICAL
RET Inhibitor
2
Active, not recruiting
RET Inhibitor
2
Active, not recruiting
SMARCA2 (BRM) Inhibitor
1
Recruiting

Sarcoma

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
CDK4/6 Inhibitor
2
Active, not recruiting
VEGF Receptor-2 Antagonist
2
Active, not recruiting

Thyroid

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
RET Inhibitor
2
Active, not recruiting
RET Inhibitor
3
Active, not recruiting